Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Cognitive and Behavioral Outcomes in Individuals With a History of Acute Disseminated Encephalomyelitis (ADEM).
Ligation of the jugular veins does not result in brain inflammation or demyelination in mice.
Regional Cervical Cord Atrophy and Disability in Multiple Sclerosis: A Voxel-based Analysis.
Towards establishing MS prevalence in Latin America and the Caribbean.
MiR-126: a novel route for natalizumab action?
Genzyme receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) application
New data at AAN to confirm efficacy of Novartis' Gilenya® across four key measures of MS disease activity, including brain volume loss
Vivitrol dosing and administration
Premorbid physical activity predicts disability progression in relapsing-remitting multiple sclerosis.
Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalomyelitis.
Association of NOD1 and NOD2 polymorphisms with Guillain-Barré syndrome in Northern Indian population.
Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells.
N-Acetylcysteine amide: A Derivative to Fulfill the Promises of N-Acetylcysteine.
Recommendations for diagnosis and management of multiple sclerosis.
Product Insert, Amiloride HCl Tablets
Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Group exercise training for balance, functional status, spasticity, fatigue and quality of life in multiple sclerosis: a randomized controlled trial.
Characterization of human platelet binding of recombinant T cell receptor ligand.
Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System.
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.
The biological significance of brain barrier mechanisms: help or hindrance in drug delivery to the central nervous system?
Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator.
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Neural stem/progenitor cells as a promising candidate for regenerative therapy of the central nervous system.
Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis.

Pages